Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
A side-by-side look at Sp 500 Equity and Multi Asset Retirement allocations, examining growth potential, risk, and diversification for retirement planning.
27,235 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
In a choppy market shaped by inflation and global tensions, three stocks stand out for potential to beat market retur...
Investors watch Nvidia for AI-driven gains, especially around key events. This guide uses history, data, and real-lif...
A single momentum-driven AI ETF is gaining attention as capex in AI hardware expands. The strategy aims to ride leade...
When a top NFL player trades the field for a nightclub mic, it isn’t just a moment of showmanship. It becomes a real-...
Investors are weighing Alibaba's prospects after a tough stretch. This guide examines whether alibaba stock rebound c...
Pinterest has shown strong quarterly results, yet the stock moves on mixed signals. This guide breaks down the what's...
A top analyst’s optimistic view on Micron highlights AI-driven memory demand and a potential upcycle in DRAM and NAND...
A landmark innovator, Ted Turner reshaped TV by launching CNN, expanding cable, and preserving Hollywood classics. Th...
HIVE Blockchain posted a standout revenue gain for the year, even as its bitcoin stash declined to 150 BTC, highlight...
Rising copper prices are fueling thefts from critical infrastructure, threatening service and lifting costs for utili...
SpaceX opened its public life with a 19% first-day jump, valuing the company at more than $2 trillion. The boom shine...